Gilead dusts off a failed Ebola drug as coronavirus spreads; Exelixis boasts positive Ph I/II data
→ Less than a year ago Gilead‘s antiviral remdesivir failed to make the cut as investigators considered a raft of potential drugs that could be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
